GET THE APP

Carbohydrate-associated epitope-based anti-cancer drugs and vacci | 29357
Journal of Cell Science & Therapy

Journal of Cell Science & Therapy
Open Access

ISSN: 2157-7013

+44 1300 500008

Carbohydrate-associated epitope-based anti-cancer drugs and vaccines


3rd World Congress on Cell Science & Stem Cell Research

November 20-22, 2013 DoubleTree by Hilton Baltimore-BWI Airport, MD, USA

Gregory Lee

University of British Columbia, Canada

Scientific Tracks Abstracts: J Cell Sci Ther

Abstract :

RP215 is a monoclonal antibody (Mab), originally generated against the OC-3-VGH cancer cell line. RP215 Mab was shown to react specifically with a carbohydrate-associated epitope, which is present on cancerous glycoproteins, known as CA215. Through molecular analysis by MALDI-TOF MS, CA215 was found to consist of antigen receptors, such as immunoglobulins and T cell receptors, other immunoglobulin superfamily proteins, such as cell adhesion molecules, and other unrelated proteins, such as mucins. Following peptide mappings and glycoanalysis with CA215, high mannose and complex bisecting structures with terminal sialic acid were detected within the N-glycans. Furthermore, as many as ten O-glycans, which were found to be structurally similar to those of mucins, were also identified. In contrast to normal B cell-derived immunoglobulins, two additional O-linked glycans were detected within cancerous immunoglobulins. Immunizations of mice with purified CA215 resulted in the predominant generation of RP215-related Mabs, indicating the immuonodominance of the CA215 carbohydrateassociated epitope. In addition, anti-idiotype (anti-id) Mabs of RP215 which were generated in rats were found to contain the internal images of the carbohydrate-associated epitope. Following immunizations of these anti-id Mabs in mice, the resulting anti-anti-id (Ab3) response in mice were demonstrated to be immunologically similar to the response generated by RP215. Based on these observations, anti-id Mabs, which carry the internal image of RP215-specific epitope, may be suitable candidates for anti-cancer vaccine development in humans.

Biography :

Gregory Lee completed his Ph.D. from California Institute of Technology and postdoctoral studies from University of California, San Diego. He became a full Professor at University of British Columbia in 1989, and retired in 2012 with the title of Professor Emeritus. He is the co-founder of Vancouver BioTech Ltd. He has published more than 200 papers, including 30 papers in cancer research. He has been serving as an editorial board member of the Journal of Carcinogenesis and Mutagenesis, and the Journal of Cancer Science and Therapy since 2012.

Email: cyglee@yahoo.com

Top